From mAbs to ADCs: Rethinking the Platform Manufacturing Model

Key Takeaways

• ADC manufacturing is unlikely to follow the mAb platform model exactly. ADCs combine antibody production with linker–payload chemistry, conjugation, formulation and high-containment requirements.

• Platform-like approaches are emerging in specific parts of the workflow. Site-specific conjugation, analytical control strategies and repeatable process frameworks are helping make ADC development more predictable.

• Formulation and stability remain major limits to standardization. Each ADC drug substance may behave differently depending on antibody, linker, payload, DAR, hydrophobicity and aggregation risk.

• For CDMOs, the ADC platform may be operational rather than universal. Integrated capabilities, high-containment infrastructure, specialized analytics and coordinated supply chains may matter more than a single standard process.

• The most realistic future is modular standardization. ADC manufacturing can become more repeatable without becoming one-size-fits-all.

Monoclonal antibodies (mAbs) offer one of the clearest examples of how a complex biologic modality can move from highly individualized process development toward more repeatable manufacturing logic. Over time, mAb production benefited from robust manufacturing platforms, familiar process architectures, and downstream strategies built around recurring unit operations. That history makes mAbs the natural reference point for any discussion of whether antibody–drug conjugates (ADCs) can follow a similar path.

The question is becoming more important as ADC development matures. ADCs are built from three interdependent components: an antibody, a linker, and a drug payload. That structure gives the modality its therapeutic promise, allowing the targeting function of the antibody to be combined with the potency of a cytotoxic payload. It also creates a manufacturing challenge that extends beyond standard antibody production. Each ADC requires control not only of the antibody itself but also of linker–payload chemistry, conjugation, product heterogeneity, quality attributes, and the overall manufacturing control strategy.

For that reason, the central question is not whether ADCs can simply copy the mAb platform playbook. A more useful question is whether ADC manufacturing can develop repeatable frameworks that improve speed, control, scalability, and technology transfer while still allowing for the molecule-specific flexibility that the modality requires. In this context, a “platform” should not be understood as one fixed process that can be applied uniformly to every ADC. It is better understood as a set of standardized or semi-standardized approaches that help manufacturers manage recurring technical challenges across programs.

That distinction matters because ADCs exist at the intersection of biologics manufacturing, synthetic chemistry, conjugation science, analytical characterization, and high-potency handling. Some parts of that workflow may lend themselves to platform-like standardization, particularly where manufacturers can define common process steps, analytical expectations, or control strategies. Other parts may remain product-specific because the behavior of each ADC depends on the particular antibody, linker, payload, and conjugation approach. The emerging ADC platform model, if one is taking shape, is therefore unlikely to look like a single universal recipe. It is more likely to be a modular framework for bringing greater consistency to a modality that still depends on careful customization.

The mAb comparison is useful because mAb manufacturing shows what platformization can mean in practice without implying that every product follows an identical process. As mAbs became a major therapeutic class, manufacturers faced pressure to move candidates through development efficiently while maintaining product quality, scalability, and commercial viability. Platform approaches helped address that pressure by giving development teams a familiar starting point rather than requiring each program to begin from first principles.¹

In downstream processing, that platform logic became especially visible. mAb purification commonly relies on a sequence of recurring operations, including cell culture harvest, protein A affinity chromatography, and additional polishing steps designed to remove impurities and support product quality. The specific conditions, resin choices, buffer systems, and process parameters still need to be adapted to the product, but the overall architecture gives manufacturers a well-understood framework for process development.²

That distinction is important for ADCs. A platform process does not eliminate development work or molecule-specific optimization. Instead, it reduces uncertainty by creating a repeatable process template that can be adjusted as needed. In the mAb context, platformization helped manufacturers build from accumulated process knowledge, analytical expectations, and operational experience. It created efficiencies because teams could anticipate many of the major development steps, risks, and control points before beginning work on a new molecule.

The limits of the mAb analogy become clear as soon as the structure of an ADC is considered. An ADC is not simply an antibody with a minor chemical modification. It is a multicomponent therapeutic that combines an antibody, a linker, and a drug payload into a single construct. That design creates the central therapeutic logic of the modality, but it also means that manufacturing must account for the behavior of each component as well as the behavior of the conjugated product as a whole.³

This places ADCs at the nexus of multiple discrete manufacturing domains. The antibody portion draws on large molecule production experience, but the linker and payload introduce synthetic chemistry requirements, and the potency of many ADC payloads requires specialized high-potency active pharmaceutical ingredient (API) handling. Conjugation then creates another layer of process complexity, requiring control over the attachment of the linker–payload to the antibody and the resulting distribution of conjugated species. The manufacturing model therefore needs to integrate biologics expertise, linker chemistry, conjugation science, analytical characterization, and containment measures designed to protect operators and facilities.⁴

That complexity makes a universal ADC process difficult to imagine. In mAb manufacturing, broadly familiar process architectures can often provide a starting framework. ADCs, by contrast, depend on variables that can change substantially from one program to another, including the antibody, linker, payload, conjugation approach, drug-to-antibody ratio (DAR), hydrophobicity, aggregation tendency, and stability profile. These variables influence not only process development but also formulation strategy and product characterization. This is why mAb platform formulations cannot simply be assumed to apply to ADCs; each ADC drug substance may present its own formulation and stability challenges.^5,6

Containment adds another distinction. For standard antibodies, manufacturing strategy is largely shaped by biologics production, purification, and quality control. For ADCs, the presence of a highly potent API (HPAPI) payload means that facility design, equipment selection, material transfer, cleaning, and operator protection become part of the manufacturing platform question. Containment is not a secondary operational detail; it affects how the process is designed, where it can be performed, and what kinds of partners or facilities are equipped to support it.⁴

These differences do not mean that ADC manufacturing cannot become more standardized. Howeover, they do mean that standardization has to be defined carefully. The most realistic opportunity is not a single ADC process that works across the modality but a set of repeatable frameworks for handling recurring sources of complexity: conjugation control, analytical expectations, formulation assessment, containment infrastructure, and integrated project execution. That more modular view preserves the useful lesson from mAbs while recognizing that ADCs require a broader and more chemically complex manufacturing model.

If ADC manufacturing has a natural platform frontier, it is conjugation. This is the step that turns an antibody, linker, and payload into the final conjugated therapeutic, and it is also where much of the modality’s product-specific complexity becomes visible. The conjugation process must support efficient attachment of the linker–payload to the antibody while preserving antibody integrity, controlling product heterogeneity, and producing a material that can be characterized, formulated, and manufactured consistently. Because of that central role, conjugation is one of the clearest places where ADC developers are pursuing more predictable and repeatable approaches.^3,7

Conventional conjugation strategies can create heterogeneous products, including variation in the number and location of payloads attached to each antibody. That heterogeneity is often captured through DAR, which is a critical quality attribute for ADCs because it reflects the average number of drug molecules attached to each antibody. Controlling DAR is not simply an analytical concern; it connects directly to process development, product consistency, and the ability to understand how changes in conjugation affect the final ADC.^7,8

This is why site-specific conjugation has become such an important direction for the field. Rather than relying only on broader chemical reactivity across naturally available sites, site-specific approaches seek to attach the linker–payload in more defined ways. The appeal is platform-like: if conjugation can be made more controlled, then one of the most variable ADC-specific steps can become more predictable across programs. AJICAP, for example, has been described as a site-specific chemical conjugation platform using IgG Fc-affinity reagents, illustrating how conjugation technologies are being developed with platform logic in mind.⁹

That does not mean site-specific conjugation solves every ADC manufacturing challenge or that one conjugation method can become universal. The antibody, linker, payload, target DAR, and desired product profile still shape process development. A conjugation platform can reduce certain kinds of variability, but it does not eliminate the need to evaluate the behavior of each ADC candidate. The more defensible conclusion is that conjugation is becoming a focus of platform-like standardization because it is the most ADC-defining step and one of the most important levers for improving control.^7,8

For manufacturers and CDMOs, this makes conjugation a strategic control point. Standardizing the approach to conjugation development, characterization, validation, and life cycle control can help create a more repeatable development framework even when the final process remains molecule-specific. In that sense, conjugation may be the first area where ADC manufacturing begins to resemble a platform, not because every ADC can use the same recipe, but because the field is building more systematic ways to manage the same underlying challenge: attaching a highly potent payload to an antibody in a controlled, reproducible, and manufacturable way.

For ADCs, platformization does not have to occur only through shared unit operations or standardized process steps. It can also emerge through the way manufacturers define, measure, and control product quality. Because ADCs are structurally more complex than their corresponding unconjugated antibodies, analytical characterization becomes a central part of the manufacturing strategy rather than a downstream confirmation step. The product must be understood not only as an antibody, but as a conjugated molecule with attributes shaped by the linker, payload, conjugation chemistry, and resulting distribution of species.^7,8

DAR is one of the clearest examples. As a measure of the average number of drug molecules attached to each antibody, DAR gives manufacturers a way to evaluate whether conjugation has produced the intended product profile. It also helps connect process decisions to product consistency, because shifts in conjugation efficiency or distribution can alter the final ADC population. DAR is more than a descriptive measurement; it is a key part of the control framework that allows developers to compare batches, monitor process performance, and understand whether the conjugation process is behaving as expected.⁸

Other analytical priorities reinforce the same point. ADC characterization must account for heterogeneity, aggregation, fragmentation, free drug, unconjugated antibody, and related impurities. These attributes matter because they reflect the combined effects of antibody integrity, linker–payload chemistry, and conjugation conditions. A process that appears acceptable from a narrow antibody-manufacturing perspective may still generate ADC-specific concerns if conjugation changes aggregation behavior, produces an undesirable distribution of species, or affects stability.^5,8

This is where control strategy becomes a platform layer. Even when each ADC requires a customized process, manufacturers can still build repeatable frameworks for identifying critical quality attributes, developing analytical methods, setting process controls, and validating that the process can consistently produce material within defined expectations. That type of standardization does not make the molecule less complex, but it makes development more systematic. It gives teams a disciplined way to evaluate the recurring questions that arise across ADC programs: how the payload is attached, how much drug is attached, how heterogeneous the product is, how stable the conjugate remains, and how changes in process conditions affect product quality.^7,8

Analytics may therefore standardize faster than the manufacturing process itself. A universal ADC process remains unlikely because antibody, linker, payload, and formulation behavior vary across programs. But many ADCs share a common need for rigorous characterization of DAR, heterogeneity, aggregation, fragmentation, and conjugation-related quality attributes. By standardizing how these issues are measured and controlled, developers and CDMOs can create a practical form of platformization that improves comparability and process understanding without forcing every ADC into the same manufacturing template.

The case for ADC platformization becomes more limited when the discussion moves from conjugation control and analytical strategy to formulation and stability. Even if manufacturers can build repeatable approaches for conjugation development, DAR measurement, and product characterization, the final ADC drug substance may still behave in ways that are difficult to predict from mAb experience alone. The antibody remains central, but the linker–payload can alter the physicochemical behavior of the molecule and create formulation challenges that do not apply in the same way to an unconjugated antibody.^5,6

This is one of the clearest reasons to avoid overstating the mAb analogy. Platform formulations used for standard mAbs may not transfer directly to ADCs because each ADC drug substance is unique. The specific antibody, linker, payload, conjugation site, and DAR can all influence the final product profile, which means formulation development must account for the properties of the complete conjugate rather than the antibody alone. ADC formulations may draw on some of the same excipients and principles used for antibodies, but they require additional attention to ADC-specific stability and compatibility concerns.

Hydrophobicity is a central issue. Linker–toxin components can increase the hydrophobic character of the ADC, and that risk can become more pronounced at higher DARs. Increased hydrophobicity can contribute to aggregation, which links formulation directly back to conjugation strategy and analytical characterization. DAR, aggregation, and product heterogeneity therefore cannot be treated as isolated issues; they interact across process development, formulation, and stability assessment.^5,8

These challenges do not mean that formulation work must remain entirely bespoke or that no platform thinking is possible. Developers may still use familiar screening strategies, excipient classes, and stability-study frameworks as starting points. The limitation is that ADC formulation often requires earlier and more careful evaluation of how the linker–payload changes the behavior of the antibody. A formulation that might appear reasonable for the unconjugated mAb may not adequately address the stability profile of the conjugated molecule.^5,6

This is where the idea of modular standardization becomes more useful than the idea of a universal ADC platform. Conjugation technologies and analytical frameworks may become increasingly repeatable, but formulation and stability will continue to test how far that repeatability can go. The practical goal is to standardize the development logic where possible: identify the known risk factors, evaluate the ADC-specific attributes early, and use analytical data to guide formulation decisions. That approach supports more consistent development without pretending that every ADC will respond to the same formulation template.

For CDMOs, the platform question becomes less about whether every ADC can follow the same process and more about whether the organization can make complex, cross-disciplinary development feel repeatable. ADC manufacturing requires coordination across large molecule production, small molecule synthesis, linker chemistry, conjugation, analytical characterization, and high-containment operations. That combination places unusual demands on outsourcing partners, because the technical handoffs between these areas can influence timelines, process understanding, and product quality.

This is where ADC platformization begins to look operational rather than purely technical. A CDMO may not be able to offer a universal ADC process, but it can build a repeatable operating model for moving programs through development. That model might include established approaches for managing linker–payload supply, conjugation process development, DAR and impurity analysis, containment strategy, and drug product coordination. The value lies in reducing friction across the full workflow, especially at the points where biology, chemistry, analytics, and facility controls intersect.

Integrated supply models reflect that need. AGC Biologics’ Proveo model, for example, describes an end-to-end ADC supply chain that includes mAb development and manufacturing, drug-linker payload, final conjugation, and fill/finish under one project-management structure. That type of positioning suggests that contract development and manufacturing organizations (CDMOs) see coordination itself as part of the ADC manufacturing challenge. The platform is not only the process in the reactor or conjugation vessel; it is also the ability to align multiple specialized activities within a single development and manufacturing pathway.¹⁰

Containment further reinforces the operational nature of the platform. ADCs that involve highly potent payloads require infrastructure and procedures designed to protect operators and prevent cross-contamination. Sterling’s reported HPAPI capability expansion to support ADC development and manufacturing, including isolator capacity for toxin–linker manufacturing for clinical and commercial production, illustrates how CDMO investment is being directed toward the physical systems needed to support these programs. In this context, containment infrastructure becomes part of the platform because it determines what kinds of ADC work can be performed safely and at what scale.¹¹

The broader CDMO market is responding to this same pressure. High-potency manufacturing has remained an active area of CDMO and contract manufacturing organization investment, with ADC demand contributing to that activity. These investments do not prove that ADC manufacturing has become standardized, but they do show that outsourcing partners are building capacity around recurring operational needs: high-containment suites, specialized equipment, trained personnel, and workflows that can support linker–payload and conjugation activities.¹²

For innovators, this changes how an ADC manufacturing partner should be evaluated. Technical capability still matters, but the differentiator may be the partner’s ability to connect capabilities that are often separated across organizations or sites. A strong ADC operating model must account for the antibody, payload, linker, conjugation process, analytical strategy, formulation requirements, containment controls, and fill/finish plan as connected parts of the same development path. When those pieces are managed independently, complexity can accumulate at every handoff. When they are managed through a coordinated framework, the process can become more predictable even if the molecule remains highly specific.

That may be the most practical form of ADC platformization for CDMOs. Rather than standardizing the product, CDMOs can standardize the infrastructure, workflows, documentation practices, analytical expectations, containment approaches, and project-management systems used to advance ADC programs. The result is not a one-size-fits-all manufacturing process. It is a more disciplined operating environment for developing and producing a class of therapies that will continue to require both repeatability and customization.

The Modular ADC Platform Model

A balanced ADC platform model should be understood as layered rather than universal. ADC manufacturing is becoming more repeatable in selected areas, but the modality remains too dependent on the specific antibody, linker, payload, conjugation approach, and formulation behavior to support a single process template. The practical question is where commonality can be standardized and where product-specific development must remain central.

mAb-Derived Process Knowledge

ADCs still begin with an antibody, so mAb production and purification experience provides an important foundation. Familiar process architectures, including established downstream approaches such as harvest, protein A affinity chromatography, and polishing, can help reduce development uncertainty before ADC-specific requirements are introduced.^1,2

ADC-Specific Conjugation Control

Conjugation is where the platform model begins to diverge from standard mAb manufacturing. Controlled and site-specific conjugation technologies aim to make linker–payload attachment more predictable and reduce some of the heterogeneity that can complicate ADC development. These approaches do not eliminate molecule-specific optimization, but they show how the field is standardizing the modality’s defining step.⁹

Analytical Standardization

Because ADCs can vary in DAR, aggregation, fragmentation, and conjugation-related heterogeneity, repeatable analytical frameworks are essential to process understanding. Analytics can function as a platform layer by giving developers a consistent way to evaluate product quality, compare batches, and identify risks across programs, even when the molecules themselves differ.⁸

Modular CDMO Infrastructure

For CDMOs, the ADC platform is increasingly operational. Integrated capabilities that connect large molecule manufacturing, linker–payload expertise, conjugation, specialized analytics, high-containment operations, and fill/finish coordination can standardize how complex interfaces are managed, even when the specific process remains product-dependent.^4,10

Molecule-Specific Optimization

The final layer is the one least suited to full standardization. Formulation, stability, hydrophobicity, aggregation risk, and final conjugate behavior can vary depending on the antibody, linker, payload, conjugation site, and DAR. A practical ADC platform therefore standardizes the framework, not the molecule, leaving room for the specific behavior of each drug substance.⁵

The future of ADC manufacturing will likely be shaped by a more disciplined understanding of where standardization is useful and where it becomes risky. A universal ADC process template may be unrealistic, but a fully bespoke model is equally unsatisfying for a modality moving toward broader clinical and commercial relevance. The opportunity lies between those extremes: building manufacturing systems that make recurring challenges more predictable without flattening the molecular differences that define each ADC.

For developers and CDMOs, that means treating platformization as a practical operating principle rather than a promise of uniformity. The strongest ADC manufacturing models will standardize the parts of development that benefit from accumulated experience while preserving enough flexibility to respond to the specific behavior of each antibody-linker-payload combination. That balance will become increasingly important as ADC pipelines diversify and more programs move from development into sustained supply.

The next stage of ADC manufacturing will not be measured by whether the field can replicate the mAb platform model exactly. It will be measured by whether manufacturers can turn complexity into a managed variable: anticipated earlier, characterized more rigorously, transferred more smoothly, and scaled with fewer surprises. In that sense, the emerging ADC platform is not a fixed recipe, but a framework for making one of oncology’s most complex therapeutic modalities more manufacturable.

1. Shukla, Abhinav A, et al. “Evolving trends in mAb production processes.” Bioengineering & Translational Medicine. 2: 58–69 (2017).

2. Liu, Hui F, et al. “Recovery and purification process development for monoclonal antibody production.” mAbs. 2: 480–499 (2010).

3. Riccardi, Federico, et al. “A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy.” Frontiers in Pharmacology. 14: 1274088 (2023).

4. “Antibody Drug Conjugate Manufacturing.” MilliporeSigma. Accessed 7 May 2026.

5. Alexander, Peter, et al. “Manufacturing Challenges of Therapeutic Antibody–Drug Conjugates.” BioProcess International. 19 Sep. 2023.

6. Duerr, Corinna, and Wolfgang Friess. “Antibody-drug conjugates — stability and formulation.” European Journal of Pharmaceutics and Biopharmaceutics. 139: 168–176 (2019).

7. Li, Meng, et al. “Antibody-Drug Conjugate Overview: a State-of-the-art Manufacturing Process and Control Strategy.” Pharmaceutical Research. 41: 419–440 (2024).

8. Wakankar, Aditya, et al. “Analytical methods for physicochemical characterization of antibody drug conjugates.” mAbs. 3: 161–172 (2011).

9. Matsuda, Yutaka, et al. “Chemical Site-Specific Conjugation Platform to Improve the Pharmacokinetics and Therapeutic Index of Antibody-Drug Conjugates.” Molecular Pharmaceutics. 18: 4058–4066 (2021).

10. “Antibody Drug Conjugates (ADC) Manufacturing & Development.” AGC Biologics. Accessed 7 May 2026.

11. Sterling Expands HPAPI Capabilities to Further Strengthen Integrated ADC Services. Sterling Pharma Solutions. 30 May 2024.

12. Van Arnum, Patricia. “A Strong Contract ADC Market Drives Expansions in High-Potency Manufacturing.” DCAT Value Chain Insights. 7 Nov. 2024.